Display options
Cite
La Rosa F, Mancuso R, Agostini S, et al. Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(11)doi: 10.3390/ph14111187.
La Rosa, F., Mancuso, R., Agostini, S., Piancone, F., Marventano, I., Saresella, M., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., & Clerici, M. (2021). Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland), 14(11), . https://doi.org/10.3390/ph14111187
La Rosa, Francesca, et al. "Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease." Pharmaceuticals (Basel, Switzerland) vol. 14,11 (2021). doi: https://doi.org/10.3390/ph14111187
La Rosa F, Mancuso R, Agostini S, Piancone F, Marventano I, Saresella M, Hernis A, Fenoglio C, Galimberti D, Scarpini E, Clerici M. Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease. Pharmaceuticals (Basel). 2021 Nov 20;14(11). doi: 10.3390/ph14111187. PMID: 34832969; PMCID: PMC8623160.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Nov 20;14(11). doi: 10.3390/ph14111187.

Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease.

Pharmaceuticals (Basel, Switzerland)

Francesca La Rosa, Roberta Mancuso, Simone Agostini, Federica Piancone, Ivana Marventano, Marina Saresella, Ambra Hernis, Chiara Fenoglio, Daniela Galimberti, Elio Scarpini, Mario Clerici

Affiliations

  1. IRCCS Fondazione Don C. Gnocchi, ONLUS, 20148 Milan, Italy.
  2. Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
  3. Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  4. Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20100 Milan, Italy.

PMID: 34832969 PMCID: PMC8623160 DOI: 10.3390/ph14111187

Abstract

Activation of the NLRP3 inflammasome complex results in the production of IL-18, Caspase-1 and IL-1β. These cytokines have a beneficial role in promoting inflammation, but an excessive activation of the inflammasome and the consequent constitutive inflammatory status is a negative factor in human pathologies including Alzheimer's Disease (AD). MicroRNAs (miR-NAs) target the 3'UTR region of NLRP3, preventing the activation of the inflammasome and inhibiting cytokine production. Because Stavudine (D4T), an antiretroviral drug, was recently shown to reduce inflammasome activation, we verified whether its effect is mediated by miR-7-5p, miR-22-3p, miR-30e-5p and miR-223-3p: miRNAs that bind the

Keywords: Alzheimer’s disease; D4T; NLRP3 inflammasome; miRNAs

References

  1. J Clin Invest. 2013 Nov;123(11):4836-48 - PubMed
  2. J Psychiatr Res. 1975 Nov;12(3):189-98 - PubMed
  3. Cell Biochem Funct. 2016 Jun;34(4):233-7 - PubMed
  4. Trends Cell Biol. 2015 May;25(5):308-15 - PubMed
  5. Mol Neurodegener. 2016 Mar 03;11:23 - PubMed
  6. PLoS One. 2013 Apr 16;8(4):e62196 - PubMed
  7. J Alzheimers Dis. 2019;72(2):401-412 - PubMed
  8. Neurobiol Aging. 2012 Mar;33(3):466-78 - PubMed
  9. Mol Cell. 2002 Aug;10(2):417-26 - PubMed
  10. Trends Pharmacol Sci. 1991 Oct;12(10):383-8 - PubMed
  11. Neurosci Bull. 2011 Apr;27(2):115-22 - PubMed
  12. PLoS One. 2017 Apr 12;12(4):e0175336 - PubMed
  13. Neurobiol Dis. 2017 Nov;107:41-56 - PubMed
  14. Science. 2014 Nov 21;346(6212):1000-3 - PubMed
  15. Cell. 2013 Apr 25;153(3):516-9 - PubMed
  16. Nat Rev Neurosci. 2015 Jun;16(6):358-72 - PubMed
  17. Hum Mol Genet. 2011 Aug 1;20(15):3067-78 - PubMed
  18. Cell. 2010 Mar 19;140(6):821-32 - PubMed
  19. Nature. 2013 Jan 31;493(7434):674-8 - PubMed
  20. Mech Ageing Dev. 1984 Nov;28(1):47-55 - PubMed
  21. J Alzheimers Dis. 2015;49(3):755-66 - PubMed
  22. Aging (Albany NY). 2010 Mar 31;2(3):166-9 - PubMed
  23. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  24. Front Pharmacol. 2019 May 01;10:451 - PubMed
  25. Front Pharmacol. 2015 Nov 05;6:262 - PubMed
  26. Immunol Rev. 2012 Jul;248(1):228-39 - PubMed
  27. Nat Immunol. 2008 Aug;9(8):857-65 - PubMed
  28. Br J Psychiatry. 1982 Jun;140:566-72 - PubMed
  29. J Cell Mol Med. 2020 Dec;24(24):14405-14414 - PubMed
  30. Lancet Neurol. 2015 Apr;14(4):388-405 - PubMed
  31. BioData Min. 2012 Oct 03;5(1):17 - PubMed
  32. Brain Res. 2010 Jun 18;1338:48-57 - PubMed
  33. PLoS One. 2018 Aug 9;13(8):e0201232 - PubMed
  34. Nat Rev Genet. 2010 Sep;11(9):597-610 - PubMed
  35. Biomed Res Int. 2015;2015:730535 - PubMed
  36. Nature. 2009 Mar 26;458(7237):514-8 - PubMed
  37. Nat Rev Genet. 2008 Feb;9(2):102-14 - PubMed
  38. Cell. 2005 Jan 14;120(1):15-20 - PubMed
  39. Neurology. 1984 Jul;34(7):939-44 - PubMed
  40. Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 - PubMed
  41. J Sci Food Agric. 2019 Mar 30;99(5):2259-2266 - PubMed
  42. Mol Med. 1998 Jul;4(7):480-9 - PubMed
  43. Nat Rev Immunol. 2013 Jun;13(6):397-411 - PubMed
  44. Brain Behav Immun. 2015 Oct;49:182-7 - PubMed
  45. Front Cell Neurosci. 2014 Sep 02;8:262 - PubMed
  46. Brain Behav. 2020 Jun;10(6):e01627 - PubMed
  47. Nat Rev Immunol. 2016 Jul;16(7):407-20 - PubMed
  48. Sci Rep. 2019 Jun 28;9(1):9393 - PubMed
  49. Nat Rev Immunol. 2011 Mar;11(3):213-20 - PubMed
  50. Nat Rev Neurosci. 2009 Dec;10(12):837-41 - PubMed
  51. J Alzheimers Dis. 2008 May;14(1):27-41 - PubMed

Publication Types